**Re-TRAINING UPDATE**

|  |  |  |  |
| --- | --- | --- | --- |
| **Lab Location:** | All labs | **Date Distributed:** | 6/16/25 |
| **Department:** | Hematology | **Due Date:** | 6/30/25 |
|  |  | **Implementation:** | **Current** |

**DESCRIPTION OF retraining**

|  |
| --- |
| **Name of procedure:** |
| Sysmex XN Series Operation for CBC and Reticulocytes (AHC.H963) |
| **Description of change(s):** |
| For labs where the pathologist is located under the same CLIA # (SGMC or WOMC) submit to pathologist, and report pathologist result per SOP. See chart below for a list of slide review requirements for differential slides. A blast or any identifiable cell, must have a Path review.  For Labs where the pathologist is located at another lab, with a separate CLIA# (GEC and FWMC) report the result on the PT result form as “would refer”. In the case of the most recent CAP survey for Hematology differentials, BCP-B 2025:  Based on the CAP master list - If an immature or abnormal cell is identified, code 108 “would refer for identification – Code 108 should be used only if you would routinely send the cell in question to an outside laboratory with another CLIA number.” |

Document your compliance with this training update by taking the quiz in the MTS system.